Tubers and tumors: rapamycin therapy for benign and malignant tumors
- 1 April 2009
- journal article
- review article
- Published by Elsevier in Current Opinion in Cell Biology
- Vol. 21 (2) , 230-236
- https://doi.org/10.1016/j.ceb.2008.12.013
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate BindingJournal of Biological Chemistry, 2007
- PRAS40 Is an Insulin-Regulated Inhibitor of the mTORC1 Protein KinaseMolecular Cell, 2007
- Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the CytoskeletonCurrent Biology, 2004
- Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward RhebCurrent Biology, 2003
- Rheb Binds Tuberous Sclerosis Complex 2 (TSC2) and Promotes S6 Kinase Activation in a Rapamycin- and Farnesylation-dependent MannerJournal of Biological Chemistry, 2003
- Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2Molecular Cell, 2003
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003
- Akt regulates growth by directly phosphorylating Tsc2Nature Cell Biology, 2002
- TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signallingNature Cell Biology, 2002
- Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt PathwayPublished by Elsevier ,2002